To characterize the TGF-β1 response of monocytic leukemia cells, we analyzed the effects of TGF-β1 on cell proliferation, differentiation, and apoptosis of human monoblastic U937 cells. Treatment of cells with TGF-β1 in the absence of growth factors significantly enhanced cell viability. Flow cytometric analysis of DNA content and CD14 expression revealed that TGF-β1 does not affect cell proliferation and differentiation. Consistent with these results was the finding that no transcriptional induction of Cdk inhibitors such as p21(Waf1), p15(INK4b), and p27(Klp1) was detected following TGF-β1 treatment. Interestingly, however, pretreatment of TGF-β1 significantly inhibited Fas-, DNA damage-, and growth factor deprivation-induced apoptosis. This antiapoptotic effect was totally abrogated by anti-TGF-β1 antibody. Quantitative RT-PCR analysis demonstrated a dose- and time-dependent transcriptional up-regulation of Bcl-X(L), suggesting its implication in the TGF-1-mediated antiapoptotic pathway. We also observed elevated expression of c-Fos and PTEN/MMAC1. But, no detectable change was recognized in expression of c-Jun, Fas, Fadd, Fap-1, Bcl-2, and Bax. Taken together, our study shows that TGF-β1 enhancement of cellular viability is associated with its antiapoptotic effect, which may result from the transcriptional up-regulation of Bcl-X(L).
|Number of pages||8|
|Journal||Experimental and Molecular Medicine|
|Publication status||Published - 1999 Sept 30|
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
- Clinical Biochemistry